Medivir is a research-based pharmaceutical company with a focus on oncology. Medivir has a leading competence within protease inhibitor design and nucleotide/nucleoside science and they are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).